UMOR progression has been correlated with extensive blood vessel growth in GBMs. A histological examination of GBM tissue reveals that these blood vessels are a chaotic network of irregularly shaped, dilated, and tortuous vessels.
junctions, selective transport, and altered pinocytotic activity. 15 We therefore performed studies to focus on identifying the morphological and phenotypic characteristics and the functions of brain ECs derived from gliomas. The results demonstrate that ECs from the glioma vasculature proliferate less than normal brain ECs. These tumor ECs, however, are highly active in the migration and secretion of angiogenic factors. These data emphasize that the tumor microenvironment significantly alters the characteristics of the normal vasculature, making these cells a potential target for antiangiogenic therapy.
Materials and Methods

Cell Culture and Reagents
Both normal brain ECs and ECs derived from GBMs were characterized using the following specific markers: vWF (Dako Corp., Carpinteria, CA) and CD105 (Ancell Corp., Bayport, MN) for ECs, GFAP (Dako Corp.) for astrocytes and glioma cells, CD11b (Immunotech, Marseilles, France) for macrophages/microglia, and SMA (Dako Corp.) for smooth-muscle cells. Cell viability was determined to be greater than 95% as assessed using the trypan blue exclusion technique. Both normal brain and brain tumor ECs were cultured in RPMI-1640 medium (Gibco, Grand Island, NY) supplemented with 100 ng/ml ECGS (Upstate Biotechnology, Inc., Lake Placid, NY), 2 mmol/L L-glutamine (Gibco), 10 mmol/L HEPES (Gibco), 24 mmol/L sodium bicarbonate (Gibco), 300 U heparin (SigmaAldrich, St. Louis, MO), 1% penicillin/streptomycin (Gibco), and 10% FCS (Omega Scientific, Inc., Tarzana, CA). The VEGF was purchased from R&D Systems (Minneapolis, MN) and the ET-1 was purchased from Bachem (Torrance, CA). The avidin-biotin complex kit and the aminoethyl carbazol substrate kit used for the immunohistochemical analyses were purchased from Vector Laboratories (Burlingame, CA).
Endothelial Cell Isolation and Cultivation
Normal and GBM-derived ECs were isolated from either normal human brain or human GBM tissue. Institutional Review Board approval was obtained to use discarded brain tissue from trauma surgeries or GBM specimens. The GBM specimens were obtained from patients with newly diagnosed or recurrent GBMs. No identification was made between tissue and the patient from whom it was obtained. The tissue was washed three times with RPMI-1640 medium containing penicillin and streptomycin. The tissue was then cut into small pieces in medium containing 2% FCS. Subsequently, fresh medium was added and the mixture was transferred to a centrifuge tube; an equal volume of a 30% dextran solution was added, bringing the mixture to a final concentration of 15%. The resulting mixture was then centrifuged for 10 minutes at 10,000 rpm to isolate the brain microvessels. The microvessel pellet was resuspended in 1 mg/ ml collagenase-dispase in RPMI-1640 medium supplemented with 2% FCS (RPMI-2% FCS) and incubated in a 37˚C water bath with a shaker for 1 hour. Subsequently, 10 ml of RPMI-2% FCS was added to the cells and centrifuged at 1200 rpm for 5 minutes. The pellet was resuspended in 20 ml of the RPMI-2% FCS and centrifuged again. The final pellet was resuspended in RPMI-1640 medium supplemented with 10% FCS, 100 ng/ml ECGS, and 10% Nu-serum culture supplement (BD BioCoat; BD Biosciences, Bedford, MA). Microvessels were plated on precoated gelatin flasks for 3 to 4 days. The medium was changed every 3 or 4 days until the cell cultures became 80% confluent. Endothelial cells were then purified from the cellular mixture by using an FACS based on the expression of dilacetylated low-density lipoprotein. Following the sorting procedure, the purity of the EC population was confirmed by immunostaining with vWF, GFAP, CD11b, and SMA. Only cells from Passages 3 through 5 were used for the experiments.
Endothelial Cell Migration Assay
Migration assays were performed using modified transwell chambers as described previously. 21 Briefly, 6.5-mm-diameter polyethylene filters (BD BioCoat; BD Biosciences), each with an 8-m pore size, were coated on both top and bottom by immersion into 0.5% gelatin for 2 hours and air-dried overnight. Subconfluent cultures of normal brain ECs were harvested using trypsin-ethylene diamine tetraacetic acid (0.05%) solution (Gibco); 5 ϫ 10 4 cells were then resuspended in RPMI-1640 medium supplemented with 1% FCS and placed on top of the filter in the upper chamber (100 l/well). Chemoattractants were placed in the lower compartment (600 l/ well). Transwell plates were incubated at 37˚C in 5% CO 2 for 6 hours. At the termination of the experiments, the medium was removed from the inserts and the remaining cells on the upper side of the chamber were removed using a wet Q-tip. The filters were stained with the Diff-Quick staining solution (Dade Behring, Inc., Newark, DE). Cells that migrated to the underside of the membrane were counted under high-power (40) magnification; 10 fields per filter were counted. All experimental groups were plated in triplicate.
The MTT Cell Growth Assay
Cells (2.5 ϫ 10 3 /well) were seeded into 96-well plates (100 l/ well) in quadruplicate experiments. The medium was changed to RPMI-1% FCS or RPMI-10% FCS immediately after attachment of the cells. At daily intervals, for 5 consecutive days, the MTT reagent was added (1:10 dilution) to the cultures for 4 hours, according to the manufacturer's instructions (Sigma-Aldrich). The medium was removed, dimethyl sulfoxide was added (150 l/well), and the color intensity of the tissue cultures, which is proportional to the cell number, was measured at 570 nm.
The BrdU Cell Proliferation Assay
Cells were seeded into 96-well plates at 2.5 ϫ 10 3 cells/well in quadruplicate experiments. The BrdU reagent was added to cells for 18 hours and their proliferation was evaluated using the BrdU Labeling and Detection Kit III (Roche Diagnostics, Indianapolis, IN). The number of proliferating cells was proportional to the absorbance at 405 nm, which was proportional to the BrdU incorporation.
Immunocytochemical Analysis
The cells were immunostained as previously described. 16 Briefly, cytocentrifuge preparations of cells were fixed in acetone, blocked with 5% normal horse or goat serum in PBS for 20 minutes, and incubated for 2 hours with rabbit anti-ET-1 antibody (Bachem, San Carlos, CA) or overnight with anti-VEGF (Chemicon International, Temecula, CA), Ki-67 (Dako Corp.), VE-cadherin (BD Pharmingen, San Diego, CA), CD31 (BD Pharmingen), CD105, CD11b, GFAP, or SMA antibodies. The slides were then incubated with biotinylated goat anti-rabbit IgG or biotinylated horse anti-mouse IgG (Vector Laboratories) for 45 minutes. Subsequently, the slides were treated with ABC Elite (avidin-biotin complex; Vector Laboratories) for 30 minutes, after which we used an aminoethyl carbazol substrate kit (Vector Laboratories) according to the manufacturer's instructions. A red precipitate identified positive staining; the slides were lightly (1 minute) counterstained with hematoxylin for nuclear definition.
Enzyme-Linked Immunosorbent Assay
Cells (10 5 cells/well) were seeded into six-well plates. After their attachment, the media in the wells were changed to RPMI-1% FCS. Supernatants from cells cultured for 48 hours in medium containing 1% FCS were collected and analyzed for VEGF and ET-1 concentrations. Quantities of secreted VEGF and ET-1 were determined using commercially available ELISA kits (R&D Systems) and following the manufacturer's instructions.
Flow Cytometry
The percentage of apoptotic cells was determined by performing annexin V-FITC staining. Briefly, subconfluent cell cultures were harvested by trypsinization, washed twice with PBS, and incubated with annexin V-FITC (BD Pharmingen) for 15 minutes. Stained cells were then analyzed using the FACScan machine with appropri-ate software (Becton Dickinson, Bedford, MA). Data, expressed as the percentage of positively stained cells per total number of cells, represented the apoptotic cell population.
The TUNEL Assay
To determine apoptosis, the commercially available ApopTag In Situ detection kit (TUNEL assay; Chemicon International) was used following the manufacturer's protocol. Briefly, cytocentrifuge preparations of cells were made and the cells were fixed with 2% paraformaldehyde. The cells were then postfixed using ethanol-acetic acid and incubated with terminal deoxynucleotidyl transferase followed by an incubation with antidigoxigenin peroxidase conjugate. Finally, the cells were incubated with the peroxidase substrate and counterstained with hematoxylin. Red nuclei represented apoptotic nuclei.
Detection of Cell Death
Normal brain ECs and ECs from GBMs were plated in 96-well plates at 7.5 ϫ 10 4 /ml (100 l/well) in quadruplicate experiments. The cells were lysed after 24 or 48 hours, depending on the experimental protocol, and the cell death detection ELISA Plus kit (Roche Diagnostics) was used to analyze the lysate for the presence of nucleosomes. Absorbance was measured at 405 nm.
Statistical Analysis
Values are presented as the means Ϯ SEMs. Statistical significance was evaluated using the Student t-test for paired comparisons. A probability value less than 0.05 was considered statistically significant.
Results
Morphological Findings
Tumor ECs isolated from glioma tissue were characterized and used in these studies. Six different cultures of these cells were collected and tested. As described in Materials and Methods, these cells were identified as pure EC cultures, based on staining with vWF ( Fig. 1 upper left) and CD105 (data not shown). At no time was there any evidence of glioma cells, glia, or macrophages in these cultures, as judged by negative staining for GFAP ( Fig. 1 upper  center) and CD11b ( Fig. 1 upper right) and positive staining for EC markers. Cultures of GBM ECs were clearly distinguishable morphologically from control ECs from normal brain. Subconfluent cultures of brain tumor ECs revealed large, flat adherent cells with small distinct nuclei and abundant cytoplasms ( Fig. 1 center left) . In contrast, subconfluent cultures of control normal brain ECs exhibited plump cells with large nuclei and limited cytoplasms (Fig. 1 center) . Normal brain ECs grown to confluence demonstrated a typical cobblestone-like appearance (Fig. 1  lower) , whereas confluent GBM ECs did not have this appearance (Fig. 1 center right) . Endothelial cells derived from GBMs were not vacuolated and were more than 97% viable, as determined using the trypan blue dye exclusion technique. Approximately 90% of the cells had this struc-Glioblastoma multiforme-derived endothelial cells ture; the remaining cells had the appearance of normal brain ECs. The morphological characteristics of ECs from brain tumor were consistent among the six different brain tumor EC cultures that were tested.
Surface and Cytoplasm Marker Expression in ECs Derived From GBMs
Based on the appearance of distinct phenotypic differences, the expression of specific surface and cellular markers was analyzed using immunocytochemical analyses. The results shown in Table 1 demonstrate a decreased expression of VE-cadherin in tumor ECs compared with normal brain ECs; more than 95% of the normal ECs stained positively for VE-cadherin, whereas staining for tumor ECs was faint. In addition, although the number of CD31-positive cells in cultures of both types of cells was similar, the distribution of staining was different. The CD31 was localized to the cell membrane in normal brain ECs and to the cytoplasm in tumor ECs (Table 1 ). Antibody to SMA stained approximately 50% of the tumor ECs but virtually none of the normal brain ECs. These data are summarized in Table 1 .
Cell Proliferation
Based on evidence that the microvessel density in gliomas is greater than that in normal brain tissue, the proliferation rates of both types of ECs were examined. Equal numbers (2.5 ϫ 10 3 cells/well) of brain tumor ECs and normal brain ECs were cultured in media containing either 1% FCS, 10% FCS, or ECGS for 24, 48, 72, or 96 hours, after which the cultures were analyzed for cell number by using the MTT assay. The results show (Fig. 2 ) that in these environments, the number of cells increased to a greater extent in normal EC cultures compared with tumor EC cultures. To confirm the actual difference in cell replication, both EC cultures were analyzed for proliferation by using BrdU incorporation. The data showed that brain tumor ECs proliferate more slowly than normal brain ECs (data not shown). To confirm these results further, both types of ECs were stained with Ki-67, an antibody used to detect proliferating cells. The results demonstrated significantly greater proliferation of normal ECs than tumor ECs (p = 0.003) (data not shown). These data were confirmed using three different brain tumor EC samples and three different normal brain EC samples.
Cell Apoptosis
To determine whether differences in the rate of growth of normal brain and tumor brain ECs were related to differences in apoptosis, several apoptosis assays were performed. The TUNEL assay demonstrated negligible apoptosis (Ͻ 1% of the cells) in both normal and tumor ECs cultured in media containing 10% FCS, for 24, 48, and 72 hours (data not shown). Incubation for 24 or 48 hours in serum-free media, however, caused significant apoptosis in normal brain ECs, with little apoptosis in the tumor EC population (p = 0.0004 at 48 hours) (Fig. 3 upper) . Cell-death ELISA assays were also performed using lysates from cultures of normal brain and tumor brain ECs grown in serum-free media for 24 and 48 hours. The data showed that cell death in normal EC cultures was significantly higher than that found in tumor EC cultures (p = 0.01 at 48 hours) (Fig. 3 center) . Using media supplemented with 1% FCS, flow cytometric analysis of annexin V-stained normal brain and tumor brain ECs revealed an increase in apoptotic cells in the normal EC population compared with the tumor ECs (Fig. 3 lower) .
Cell Function
Because the tumor vasculature is actively participating in angiogenesis in gliomas, the question was raised whether these tumor ECs function differently in specific angiogenic processes, compared with normal ECs. Endothelial cell migration is critical to angiogenesis and, therefore, migration was tested using a modified Boyden chamber technique. Both tumor and normal ECs (5 ϫ 10 4 cells each) were placed on top of a porous filter, and after 6 hours, the numbers of cells migrating through the pores were counted. The results show greater migration of tumor ECs than normal ECs (p = 8 ϫ 10 Ϫ7 ) (Fig. 4) . These results were consistent using three different tumor EC and three different normal brain EC cultures. Thus the tumor ECs were intrinsically more active in the absence of a chemotaxis agent. When chemotactic factors such as ET-1 and VEGF were added to the lower chamber, the migration rate of normal ECs in- creased, whereas the tumor ECs were unresponsive to these factors (Fig. 4) . The concentrations of VEGF and ET-1 used were the optimal for normal brain EC migration as determined by testing different concentrations (ET-1, 1-1000 nM; VEGF, 1-30 ng/ml). The tumor ECs did not respond at any of the concentrations tested (data not shown).
To determine whether brain tumor ECs were active in the production of growth factors, both normal and tumor ECs were cultured in 1% FCS for 48 hours and supernatants were tested for the angiogenic factors VEGF and ET-1. The data demonstrated that unstimulated brain tumor ECs constitutively produced more VEGF-1 and ET-1 than unstimulated normal brain ECs (p = 0.008 for ET-1 and p = 0.02 for VEGF) (Fig. 5) . Immunostaining with anti-ET-1 antibody showed that more than 95% of tumor and normal ECs were positive for ET-1, but tumor ECs exhibited significantly more intense staining compared with normal ECs. In addition, in the normal brain ECs, the staining pattern of ET-1 was associated with the plasma membrane, whereas in the tumor ECs, staining appeared to be diffusely distributed throughout the cytoplasm (data not shown). To determine the percentage of population that produced VEGF, an immunocytochemical analysis was performed on both types of ECs. The results demonstrated that more than 95% of the ECs were producing VEGF, but the intensity of staining was significantly greater in ECs derived from GBMs (data not shown).
Discussion
Angiogenesis is a critical requirement for solid tumor growth. 18 The infiltrating blood vessels may be derived from preexisting normal, neighboring benign-tissue vasculature, 12 from circulating endothelial progenitor cells, 1 or a combination of both sources. 4 What is becoming apparent is that extensive exposure of normal endothelium to the tumor microenvironment results in an altered phenotype and aberrant functions of ECs within the tumor, particularly glioma-derived brain ECs. The in vitro studies presented here were performed on ECs derived from human GBM tissue. These cells were determined to be pure ECs, as documented by immunostaining. In contrast to normal brain ECs, ECs derived from GBMs exhibited SMA expression, in addition to common EC markers (vWF, CD105, and CD31). Reportedly SMA is expressed on smooth-muscle cells and pericytes 2 and is not a typical EC marker. Because ECs derived from tumor were consistently vWF and CD105 positive, we suggest that these brain tumor ECs have the unique property of expressing both endothelial and pericyte mark-
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Glioblastoma multiforme-derived endothelial cells Both types of cells were also cultured in serum-free media for 24 and 48 hours and assayed using the nucleosomal release cell death assay. The data are expressed as absorbance at 405 nm, which is proportional to the number of dead cells per well. Each experiment was performed in quadruplicate (center). Both cell types were cultured in 1% FCS media for 72 hours and then stained for annexin V. The data were analyzed using flow cytometry and expressed as the percentage of cells that stained positively for annexin V-FITC per total population (lower).
ers. The brain tumor ECs tested in the present studies were derived from six different GBM specimens obtained at surgery. We believe that this tissue heterogeneity makes our data even more compelling because the data that we report were observed in all the specimens. Moreover, because there is significant heterogeneity based on genetic diversity as well as previous adjunctive treatments of the human tissue samples, all observations and experiments were based on data from at least three different tumor specimens. Thus the in vitro model used here to study brain tumor ECs is likely to have the general characteristics of GBMs and should provide direct information regarding the properties of glioma vasculature.
A common feature of all the brain tumor EC cultures that we examined is their unique morphological characteristics. This is consistent with evidence that these cells function differently. The data show that brain tumor ECs migrate faster than normal brain ECs. This migration is not based on chemotaxis, but more on random movement (chemokinetic), indicating that brain tumor ECs are active in the absence of exogenous factors. Other evidence that brain tumor ECs are constitutively activated cells is derived from data showing that these ECs actively secrete the growth factors VEGF and ET-1, as demonstrated by immunostaining and ELISA. These growth factors are likely to activate brain tumor ECs in an autocrine fashion, resulting in greater migration and stimulation of growth factor production. Both VEGF and ET-1 were reported to be effective in stimulating EC migration. 14, 16, 21 Both brain tumor and normal brain ECs express receptors for these angiogenic factors, as identified by flow cytometry and immunocytochemical analysis (data not shown). The reason for this lack of response in tumor ECs to VEGF or ET-1 is not clear; however, the constant presence of these growth factors may saturate the receptors, thus causing nonresponsiveness. Studies are underway to test this hypothesis. The mechanisms responsible for increased brain tumor EC activity are not clear; however, the autocrine effect of these factors on the ECs may, at least in part, be responsible for this enhanced activity.
A surprising finding presented here is that brain tumor ECs proliferated at a lower rate than normal brain ECs. These data were confirmed by performing the MTT assay and measuring BrdU incorporation and Ki-67 expression. This decreased proliferation of brain tumor ECs was observed in both FCS-enriched (10%) and low-serum (1%) media. These results contrast with a previous observation that tumor ECs have a high rate of proliferation compared with the normal endothelium. 6 This discrepancy may be due to the fact that in this previously published study tumor tissue explants were examined in vivo, whereas in our studies we tested purified, characterized GBM-derived ECs. In addition, our results are consistent with observations that there may be a temporal dichotomy between migration and proliferation, because glioma cells with decreased motility demonstrate increased proliferation. 7 The decreased number of brain tumor ECs in culture is not a reflection of increased apoptosis. Our studies show that levels of apoptosis for both normal brain and brain tumor ECs were relatively low under optimal growth conditions; however, in suboptimal conditions (that is, low-serum or serum-free medium) there was less apoptosis in the brain tumor EC population. This is consistent with published data 4 that demonstrate that renal carcinoma-derived ECs have increased survival and increased expression of the antiapoptotic protein Bcl-2. Indeed, complementary DNA microarray studies have shown that migrating cells have a global downregulation of proapoptotic genes and upregulation of antiapoptotic genes. 19, 20 This is also consistent with our data showing that brain tumor ECs constitutively produce the survival factor VEGF. 4 Thus ECs derived from GBMs exhibit enhanced survival and are functionally active in the tumor microenvironment.
Brain tumor ECs were shown in the present studies to have altered expression of CD31 (also known as platelet endothelial cell adhesion molecule-1 or PE-CAM-1), and CD144 (VE-cadherin), as demonstrated by immunostaining. In ECs derived from brain tumors (GBMs), CD31 was present in the cytoplasm, whereas in normal brain ECs, CD31 was predominantly expressed on the cell surface. A receptor present on both ECs and leukocytes, CD31 is involved in leukocyte transmigration, angiogenesis, and apoptosis. 13 It has previously been shown that there are low numbers of infiltrating cytotoxic T cells in gliomas. 9 This may be due to a diminished leukocyte-endothelium interaction and a subsequent reduced cell transmigration. Based on these studies, the altered distribution and expression of CD31 on brain tumor EC membranes may be an excellent subject for investigation. Because CD144 is known to be critical for angiogenesis, blocking CD144 leads to abnormal capillary junctions and aberrant tubule formation. 9, 24 Our studies demonstrate that VE-cadherin is significantly reduced in brain tumor ECs; this lack of junctional proteins may contribute to tumor blood vessel leakiness and abnormal structures. 5 There are several reports of reduced CD105 expression on tumor microvessels 10 and contradictory reports regarding CD34 expression. 11, 23 In our studies, we have not detected any differences between normal brain ECs and brain tumor ECs with respect to CD34 and CD105 expression (data not shown).
Our data demonstrated phenotypic and functional differences between normal brain ECs and brain tumor ECs. It is unclear whether genotypic differences are also present in these two distinct populations and, if so, whether these genotypic differences are permanent or transient secondary to the tumor microenvironment. Recently, St. Croix and coworkers 22 have demonstrated that tumor and normal endothelium are distinct at a genetic level. In a comparison of gene expression levels of ECs derived from blood vessels of normal and malignant colorectal tissues, these authors found differential expression and selective upregulation of endothelial-derived genes in tumor and normal endothelium. 22 This differential gene expression of ECs may be secondary to distinct angiogenic states. 
Conclusions
We have demonstrated that ECs derived from GBMs have proliferation, migration, adhesion, and growth factor production properties that differ from those of normal brain ECs. These different properties may be the key to understanding the mechanism by which normal brain ECs gain the characteristics of brain tumor ECs. This knowledge will provide information leading to the treatment of gliomas through selective antiangiogenic chemotherapy.
